Overview
Keeping up with new information about non-small cell lung cancer (NSCLC) is daunting. Digesting and applying new information to clinical practice, that’s another hurdle. This accredited series is intended to help clinicians streamline the process. Each month, the editorial board of physician experts in the care of persons with NSCLC reviews the literature to identify 1 or 2 “hot-off-the-press” publications that deserve the spotlight. During a 15-minute peer-to-peer exchange, an editorial board member gains insight from the principal investigator as to why and how the trial was conducted and its implications for clinical practice.
This course is brought to you in partnership with our sister company freeCME. Clicking the Add to Cart button will take you to the freeCME website where you can access this course for FREE.
Goals and Learning Outcomes
Upon completion of this activity, participants should be better able to:
- Assess pharmacology mechanisms and biomarker utilization for novel and emerging therapies for advanced/metastatic NSCLC.
- Describe emerging evidence and clinical data related to treatment advances for patients with metastatic/advanced NSCLC to improve clinician understanding and appreciation for novel therapies.
- Incorporate novel therapies and treatment strategies into the management of patients with advanced/metastatic NSCLC consistent with evolving evidence and practice guidelines.
Faculty
Jamie E. Chaft, MD
Attending Physician
Thoracic Oncology
Memorial Sloan Kettering Cancer Center
New York, New York
Isabel Preeshagul, DO, MBS
Thoracic Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, New York
Course Details
FREECME2026-04-21
Accreditations
This course is being provided by a Relias LLC strategic partner. Consumption of this course will take place on the partners site and courses provided in this manner are not accredited by Relias LLC.